Abbott Laboratories (ABT) Non-Current Assets (2009 - 2026)

Abbott Laboratories has disclosed Non-Current Assets across 18 years of filings, most recently posting $84.9 billion for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $84.9 billion, up 45.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $264.5 billion (up 22.17% YoY), and the FY2025 annual result was $60.7 billion, up 5.12% from the prior year.
• Non-Current Assets came in at $84.9 billion for Q1 2026 at Abbott Laboratories, up from $60.7 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $84.9 billion in Q1 2026 to a low of -$22.3 billion in Q4 2022.
• The 5-year median for Non-Current Assets is $50.5 billion (2023), against an average of $50.3 billion.
• Across the five-year window, Non-Current Assets tumbled 270.54% in 2022 and surged 326.24% in 2023, its largest moves.
• Abbott Laboratories' Non-Current Assets stood at -$22.3 billion in 2022, then soared by 326.24% to $50.5 billion in 2023, then advanced by 14.27% to $57.8 billion in 2024, then grew by 5.12% to $60.7 billion in 2025, then soared by 39.86% to $84.9 billion in 2026.
• The last three Non-Current Assets figures came in at $84.9 billion (Q1 2026), $60.7 billion (Q4 2025), and $59.3 billion (Q3 2025), per Business Quant data.